Seeking Alpha

An FDA advisory panel starts a two-day meeting to discuss Avandia, GlaxoSmithKline's (GSK +0.4%)...

An FDA advisory panel starts a two-day meeting to discuss Avandia, GlaxoSmithKline's (GSK +0.4%) former blockbuster diabetes pill whose sales plummeted after the agency said in 2010 that it could only be used only in rare cases due to fears that it caused heart attacks. The options are to remove, modify or leave Avandia's safety restrictions in place, or withdraw the drug entirely. However, even if the FDA eases those restrictions, sales of Avandia aren't expected to significantly increase. (Webcast)
From other sites
Comments (1)
  • TwistTie
    , contributor
    Comments (2476) | Send Message
     
    It's always great to hear that the companies you invest in have committed healthcare fraud in a big way.

     

    Sheesh!
    5 Jun 2013, 01:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs